2017
DOI: 10.1016/j.bbmt.2016.12.263
|View full text |Cite
|
Sign up to set email alerts
|

A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells

Abstract: CD34 counts do not need to be checked prior to D12. There were a number of variables in the collection process including time to start GCSF after chemotherapy completion and the decision to use plerixafor. We propose to start GCSF the day after completion of the chemotherapy and start checking CD34 on D12 of the cycle. If the patients have not started collection by D13 due to inadequate CD34 count then plerixafor should be given the evening of D13 for collection on D14. A cost analysis of standard practice vs … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Peripheral blood hematopoietic progenitors were mobilized as previously reported. 14,15 After granulocytes reached ≥0.5 × 10 9 /L patients were given rituximab (1000 mg) as a single dose.…”
Section: Mobilization and Conditioning Apheresis And Autograftingmentioning
confidence: 99%
See 1 more Smart Citation
“…Peripheral blood hematopoietic progenitors were mobilized as previously reported. 14,15 After granulocytes reached ≥0.5 × 10 9 /L patients were given rituximab (1000 mg) as a single dose.…”
Section: Mobilization and Conditioning Apheresis And Autograftingmentioning
confidence: 99%
“…5 The role of cytokines such as IL-17, IFN-y, TNF-a, IL-2, IL-22, IL-21, IL-10, MCP-1(CCL2), MIP-1A (CCL3), and MIP-1B (CCL4) in the physiopathology of MS has been studied, mostly individually, in peripheral blood and/or cerebrospinal fluid, with heterogeneous, sometimes conflicting, results. [5][6][7][8][9][10][11][12] Autologous hematopoietic stem cell transplantation (AHSCT) has been employed in MS for at least two decades; with variable results, 13 recent reports on the procedure and its feasibility have been published, 14,15 and increased intra-apheresis recruitment of CD34 + hematopoietic stem cells in autografted MS patients after G-CSF stimulation and cyclophosphamide-based conditioning has been recently reported. 16 Changes in serum cytokines implicated in MS pathophysiology before and after AHSCT have not been reported.…”
Section: Introductionmentioning
confidence: 99%
“…How do MSCs improve renal lesions? MSC therapy has been reported to exert beneficial effects on renal impairment in animal models and patients [48][49][50]. However, the exact mechanisms of nephroprotection of MSCs remain unclear at present.…”
Section: Discussionmentioning
confidence: 99%